Drugs / JS1-1-01
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05656274 | Nov 2022 → Jul 2023 | — | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06259526 | Dec 2023 → Oct 2024 | depressive disorder | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07485595 | Apr → Dec 2026 expected | depressive disorder | Tasly Pharmaceutical Group Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS1-1-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07485595 ↗ |